Strs Ohio Trims Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Strs Ohio decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 537,850 shares of the company’s stock after selling 28,711 shares during the quarter. Strs Ohio’s holdings in Teva Pharmaceutical Industries were worth $16,200,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TEVA. AQR Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after acquiring an additional 4,732 shares in the last quarter. Focus Partners Wealth raised its holdings in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after purchasing an additional 1,739 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $255,000. Flow Traders U.S. LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth about $238,000. Finally, Cerity Partners LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 2.9% in the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after purchasing an additional 1,291 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the sale, the chief accounting officer owned 20,016 shares of the company’s stock, valued at approximately $720,576. This represents a 34.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares in the company, valued at $2,247,375.57. The trade was a 25.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 465,931 shares of company stock worth $16,332,989. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.2%

Shares of NYSE TEVA opened at $34.55 on Friday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The firm has a fifty day moving average of $33.96 and a 200-day moving average of $32.55. The stock has a market capitalization of $39.73 billion, a PE ratio of 25.98, a P/E/G ratio of 4.23 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.